| 【Objective】The antitumor immune responses are predominantly governed by the Tlymphocyte-mediated immunity. However, the immune status in the development ofmalignancies is still not fully understood. The proportion of T lymphocytes and the cellsubsets in peripheral blood of patients with NSCLC were determined by flow cytometry.The distribution of Th17cells in tumor tissues with NSCLC were assessed byimmunohistochemistry. The aim of this study is to explore the changes of the cellularimmune function in the development of NSCLC and find an effective indicator to evaluatethe immune function in patients with NSCLC.【Methods】A total of ninety-nine patients with newly diagnosed non-small cell lung cancer(NSCLC) were involved in the study from May2011to December2011, and22healthyvolunteers were recruited as normal controls (NCs). The proportion of CD4~+T、CD8~+T、Th1（CD4~+IFN-γ~+）、Tc1（CD8~+IFN-γ~+）、Th17（CD4~+IL-17~+）、Tc17（CD8~+IL-17~+）、Treg（CD8-Foxp3~+）cells in blood samples were analyzed by flow cytometry and theconcentrations of cytokine IL-17in serum were measured by enzyme-linkedimmunosorbent assay (ELISA).The Immunohistochemistry(IHC) was used to determineIL-17expression in tissues with NSCLC,and the mRNA expression levels of IL-17intumor tissues were investigated by real-time fluorescence quantitative PCR (real-timePCR).【Results】1. Compared with normal controls, The CD4~+T cells ratio in peripheral blood ofpatients with NSCLC were decreased, but the difference was not statistically significant, but the CD8~+T cells were decreased significantly (9.21±0.82vs26.39±1.32, P<0.001),while CD4~+/CD8~+higher than normal controls (2.74±0.17vs1.67±0.10,P<0.05).Forfurther analysis, The levels of CD4~+T and CD8~+T had no significant differences betweenvarious histological types, but degree of decline is more serious in higher clinical phase.2. Compared with normal controls, patients with NSCLC showed lower quantificationof Th1cells (12.01±0.87%vs15.73±1.27%, P<0.05)3. Compared with normal controls,patients with NSCLC showed higher quantificationof Treg cells(3.58±0.21%vs1.98±0.23%,P<0.05). For further analysis,the degree of ascentis more serious in higher clinical phase.4. Compared with normal controls,patients with NSCLC showed higher quantificationof Th17cells. For further analysis, patients with advanced disease(stageⅢ-Ⅳ) were higherthan early disease(stageⅠ-Ⅱ)(2.05±0.17%vs1.37±0.18%, P<0.05), and there are nocorrelation with histological types.5. Compared with normal controls, the concentration of IL-17showed no change inplasma(1.81±0.31pg/ml vs1.08±0.18pg/ml,P>0.05).6. Compared with normal controls,patients with NSCLC showed lower quantificationof Tc17cells (0.56±0.05vs0.84±0.13, P<0.05),but there were no difference in Tc1cells.7. Compared with normal controls,Th1/Treg in patients with NSCLC was decreased,and the degree of decline is more serious in higher clinical phase.8. The expression ofCD4~+IL-17~+cells in intratumor tissues(8.69±1.26) were higherthan proximal peritumor tissues(2.70±0.53)and distal peritumor tissue(0.62±0.15)(P<0.05).The expression of IL-17mRNA in intratumor tissues(0.30±0.07) were higher than proximalperitumor tissues(0.11±0.02)and distal peritumor tissue(0.06±0.02)(P<0.05).【Conclusion】1、In the peripheral blood of NSCLC, the helper T cells(CD4~+T、Th1cells) andcytotoxic T cells (CD8~+T、Tc17cells)were decreased, while inhibiting cells(Treg andTh17cells) were increased, suggesting that the immune function of NSCLC patients wereimpaired2、There are higher quantification of Th17cells in the peripheral blood andintratumor tissues, and had correlation with the clinical stage.The Thl7cells may beinvolved in the development of NSCLC. Their levels can be serve as a new indicator toassess the immune function of patients with NSCLC. 3、In the peripheral blood of NSCLC, the Tc17cells were decreased, which mayaffect the development of NSCLC.4、In the peripheral blood of NSCLC, Th1/Treg were decreased significantly, anddegree of decline is more serious in higher clinical phase,which maybe a new indicator toassess the immune function of patients with NSCLC. |
PDF Full Text Request